ARS Pharmaceuticals, Inc (SPRY) stock news · rev $84.3M
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
This SPRY news page leads with what ARS Pharmaceuticals, Inc filed — not a scraped headline mill.
No cached 8-K sentence for SPRY yet. We will not pad this page with generic market recap.
Latest reported SPRY revenue for 2025-12-31 was $84.3M. Net income was -$171.3M. Revenue was down 5.5% from 2024-12-31 to 2025-12-31. SPRY currently screens at market cap $983.1M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the SPRY stock page; for the tape open the quote page.
SPRY stock news FAQ
What are SPRY's latest revenue and net income?
Latest cached ARS Pharmaceuticals, Inc (SPRY) revenue for Dec 31, 2025 was $84.3M. Net income was -$171.3M. Statements: https://lician.com/financials/spry
How did SPRY revenue change from the prior cached period?
Cached ARS Pharmaceuticals, Inc (SPRY) revenue was down 5.5% from $89.1M (Dec 31, 2024) to $84.3M (Dec 31, 2025). Statements: https://lician.com/financials/spry
What is SPRY's market cap?
ARS Pharmaceuticals, Inc (SPRY) market cap is $983.1M on the latest cached fundamentals snapshot.
What kind of company is SPRY?
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Where is SPRY stock news listed?
Cached stock news for ARS Pharmaceuticals, Inc (SPRY) is listed at https://lician.com/news/spry. Filings: https://lician.com/sec/spry
Not investment advice.